Siltuximab (INN, trade name Sylvant; also known as CNTO 328, anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It binds to interleukin-6.[2][3] Siltuximab has been investigated for the treatment of neoplastic diseases:[4] metastatic renal cell cancer,[5] prostate cancer,[6] other types of cancer,[7] and for Castleman's disease.[8][9]
On April 23, 2014, siltuximab was FDA approved under the brand name of Sylvant[10] for the treatment of patients with idiopathic multicentric Castleman's disease (iMCD) who do not have human immunodeficiency virus (HIV) or human herpesvirus-8 (HHV-8).[11][12]
^"Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
^"Siltuximab mechanism of action". HemOnc.org - A Free Hematology/Oncology Reference.
^Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA (January 2017). "TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis". Cytokine. 89: 127–135. doi:10.1016/j.cyto.2016.01.021. PMID 26854213.
^Rossi JF, Négrier S, James ND, Kocak I, Hawkins R, Davis H, et al. (October 2010). "A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer". British Journal of Cancer. 103 (8): 1154–62. doi:10.1038/sj.bjc.6605872. PMC 2967052. PMID 20808314.
^Karkera J, Steiner H, Li W, Skradski V, Moser PL, Riethdorf S, et al. (September 2011). "The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study". The Prostate. 71 (13): 1455–65. doi:10.1002/pros.21362. PMID 21321981. S2CID 32034042.
^"Siltuximab". ClinicalTrials.gov.
^van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al. (August 2010). "Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease". Journal of Clinical Oncology. 28 (23): 3701–8. doi:10.1200/JCO.2009.27.2377. PMID 20625121.
Siltuximab (INN, trade name Sylvant; also known as CNTO 328, anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse...
treatment for iMCD is anti-IL-6 therapy with siltuximab (or tocilizumab, if siltuximab is not available). Siltuximab is the only FDA-approved treatment for...
features of iMCD, and blockade of the IL-6 pathway using the medications siltuximab and tocilizumab effectively treats some patients with iMCD. However, many...
antibody preparation directed against B cells bearing the CD20 antigen, or siltuximab, a monoclonal antibody preparation directed against interleukin-6, may...
Global Information
(what is this?) (verify)